Savara Inc(SVRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SVRA Savara Inc

交易中 04-29 15:36:40 EDT

4.85

-0.17

-3.49%

最高5.01	最低4.84	成交量71.43万
今开4.99	昨收5.02	日振幅3.49%
总市值9.92亿	流通市值5.57亿	总股本2.05亿
成交额349.47万	换手率0.62%	流通股本1.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":4.845,"timestamp":1777491395662,"preClose":5.02,"halted":0,"volume":714312,"delay":0,"changeRate":-0.03486055776892427,"floatShares":114999999,"shares":204657499,"eps":-0.535012,"marketStatus":"交易中","change":-0.175,"latestTime":"04-29 15:36:40 EDT","open":4.992,"high":5.01,"low":4.835,"amount":3494743.601832,"amplitude":0.034861,"askPrice":4.85,"askSize":650,"bidPrice":4.84,"bidSize":1152,"shortable":3,"etf":0,"ttmEps":-0.535012,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777492800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.02,"preHourTrading":{"tag":"盘前","latestPrice":5,"preClose":5.02,"latestTime":"09:29 EDT","volume":917,"amount":4597.4395635,"timestamp":1777469396021,"change":-0.02,"changeRate":-0.003984,"amplitude":0.031873},"postHourTrading":{"tag":"盘后","latestPrice":5.02,"preClose":5.02,"latestTime":"16:10 EDT","volume":16643,"amount":83547.86,"timestamp":1777407004899,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6024,"impliedVol":0.5629,"impliedVolPercentile":0.1952},"requestUrl":"/m/hq/s/SVRA","defaultTab":"news","newsList":[{"id":"1168628720","title":"Savara Inc：处方药使用者付费法案目标审评日期延长三个月至2026年11月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=1168628720","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168628720?lang=zh_cn&edition=full","pubTime":"2026-04-16 04:06","pubTimestamp":1776283576,"startTime":"0","endTime":"0","summary":"生物制药公司Savara Inc宣布，美国食品药品监督管理局（FDA）已将其核心在研药物的处方药使用者付费法案（PDUFA）目标审评日期延长三个月。新的最终决定期限设定为2026年11月22日。\n此次延期为FDA完成对该公司新药申请（NDA）的全面审查提供了额外时间。PDUFA日期延后通常意味着监管机构需要更多数据或信息来做出最终批准决定，这在此类审查过程中属于常规程序。\n该公司表示将继续与FDA密切合作，以推进该药物的审评进程。此次延期不影响公司对其研发管线推进的战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106015571","title":"Savara宣布美国FDA延长莫格司亭吸入溶液治疗自身免疫性肺泡蛋白沉积症的生物制品许可申请审评周期","url":"https://stock-news.laohu8.com/highlight/detail?id=1106015571","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106015571?lang=zh_cn&edition=full","pubTime":"2026-04-16 04:05","pubTimestamp":1776283522,"startTime":"0","endTime":"0","summary":"生物制药公司Savara Inc近日披露，美国食品药品监督管理局已决定延长其核心产品莫格司亭吸入溶液用于治疗自身免疫性肺泡蛋白沉积症的生物制品许可申请的审评时限。此次审评周期延长意味着监管机构需要更多时间对申报资料进行全面评估，但并未要求企业提交额外数据。该药物作为罕见呼吸系统疾病的重要候选疗法，其审评进展备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176735830","title":"Savara宣布英国MHRA受理Molgradex治疗自身免疫性肺泡蛋白沉积症的上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1176735830","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176735830?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:21","pubTimestamp":1775564504,"startTime":"0","endTime":"0","summary":"Savara Inc宣布，英国药品和保健品管理局（MHRA）已正式受理其药物Molgradex用于治疗自身免疫性肺泡蛋白沉积症的上市许可申请。\n根据公司披露的时间表，MHRA对Molgradex上市许可申请的决定预计将在2026年第四季度公布。与此同时，美国食品药品监督管理局（FDA）针对Molgradex生物制品许可申请设定的处方药用户付费法案目标日期为2026年8月22日。此外，欧洲药品管理局人用药品委员会对Molgradex上市许可申请的决定预计将于2027年第一季度作出。\n","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199822860","title":"Savara宣布英国药品和保健品管理局接受Molgradex上市许可申请用于治疗自身免疫性肺泡蛋白沉积症","url":"https://stock-news.laohu8.com/highlight/detail?id=1199822860","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199822860?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:06","pubTimestamp":1775563586,"startTime":"0","endTime":"0","summary":"Savara Inc. 宣布，英国药品和保健品管理局（MHRA）已正式受理其药物Molgradex®用于治疗自身免疫性肺泡蛋白沉积症（autoimmune PAP）的上市许可申请（MAA）。这一进展标志着该药物在英国监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115780051","title":"Savara宣布欧洲药品管理局验证Molbreevi*治疗自身免疫性肺泡蛋白沉积症的上市授权申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1115780051","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115780051?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:10","pubTimestamp":1774872613,"startTime":"0","endTime":"0","summary":"Savara Inc宣布，其针对自身免疫性肺泡蛋白沉积症（Autoimmune PAP）的治疗药物Molbreevi*的上市授权申请（MAA）已获得欧洲药品管理局（EMA）的正式验证。这一关键进展标志着该药物的审评程序在欧洲市场正式启动，为罕见呼吸系统疾病患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618990263","title":"Savara, Inc.盘中异动 大幅拉升5.16%报5.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618990263","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618990263?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:51","pubTimestamp":1773150685,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日21时51分，Savara, Inc.股票出现波动，股价快速拉升5.16%。截至发稿，该股报5.71美元/股，成交量9.1595万股，换手率0.05%，振幅4.79%。Savara, Inc.股票所在的生物技术行业中，整体涨幅为1.98%。其相关个股中，Longeveron Inc.、Mink Therapeutics, Inc.、Acurx Pharmaceuticals, Inc.涨幅较大，Biorestorative Therapies, Inc.、Mink Therapeutics, Inc.、Scisparc Ltd.较为活跃，换手率分别为576.95%、233.82%、145.88%，振幅较大的相关个股有Longeveron Inc.、Acurx Pharmaceuticals, Inc.、Artelo Biosciences, Inc.，振幅分别为54.24%、28.12%、20.22%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310215125a6b5a7f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310215125a6b5a7f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189257207","title":"Savara收到美国FDA第74日函件 显示该机构无计划召开咨询委员会会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1189257207","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189257207?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:08","pubTimestamp":1772831294,"startTime":"0","endTime":"0","summary":"Savara Inc（纳斯达克代码：SVRA）近日宣布，已收到美国食品药品监督管理局（FDA）发出的第74日函件。该函件明确指出，FDA目前并无召集咨询委员会会议的计划。\n这一进展标志着Savara在监管审批流程中迈出了重要一步。通常情况下，FDA会通过咨询委员会会议对创新疗法进行深入评估，而此次无需召开此类会议的决定，可能预示着审批流程的加速。\n公司表示将继续与FDA保持密切沟通，积极推进相关药物的审评工作。市场关注此举是否意味着Savara的研发项目将获得更快的监管反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163688181","title":"Savara公布Molbreevi*治疗自身免疫性肺泡蛋白沉积症研发项目的监管进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1163688181","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163688181?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:06","pubTimestamp":1772831205,"startTime":"0","endTime":"0","summary":"Savara Inc（简称Savara）近日就其针对自身免疫性肺泡蛋白沉积症（Autoimmune PAP）的Molbreevi*研发项目，发布了最新的监管动态。\n公司方面表示，相关进展将有助于推动该疗法的后续开发进程，为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100831277","title":"Master Tec集团宣布Sediacom获1050万令吉授标函","url":"https://stock-news.laohu8.com/highlight/detail?id=1100831277","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100831277?lang=zh_cn&edition=full","pubTime":"2026-03-06 18:35","pubTimestamp":1772793354,"startTime":"0","endTime":"0","summary":"3月6日 - Master Tec集团宣布，其子公司Sediacom已正式接受价值1050万令吉的工程、采购、施工和调试（EPCC）合约。该合约内容涵盖275千伏地下电缆项目及国家能源公司（TNB）开关站扩建工程。\n此次中标将进一步巩固Master Tec在能源基建领域的市场地位，为公司未来业绩提供新的增长动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113859266","title":"Savara宣布美国FDA受理Molbreevi*治疗自身免疫性肺泡蛋白沉积症的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1113859266","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113859266?lang=zh_cn&edition=full","pubTime":"2026-02-21 05:15","pubTimestamp":1771622112,"startTime":"0","endTime":"0","summary":"Savara Inc（简称Savara）近日宣布，其针对自身免疫性肺泡蛋白沉积症（Autoimmune PAP）的候选药物Molbreevi*的生物制品许可申请（BLA），已正式获得美国食品药品监督管理局（FDA）受理。\n这一进展标志着Molbreevi*在监管审批进程中迈出关键一步，为自身免疫性肺泡蛋白沉积症患者带来新的治疗希望。FDA的受理意味着该申请已通过初步审查，并进入实质性审评阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105603539","title":"Savara与Hercules Capital修订债务协议 获FDA批准后可追加7500万美元融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1105603539","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105603539?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:06","pubTimestamp":1769519194,"startTime":"0","endTime":"0","summary":"Savara Inc宣布与Hercules Capital达成债务融资协议修订条款。根据新条款，一旦其核心药物Molbrevim获得美国食品药品监督管理局批准，公司将获得最高7500万美元的追加债务融资额度。此次协议修订强化了Savara的资本灵活性，为Molbrevim的商业化进程提供关键资金支持。通过结构化融资安排，公司可在新药获批后迅速激活额外资金流，加速市场布局。目前Molbrevim正处于FDA审评的关键阶段，此次融资条款的优化被视为Savara应对监管决策的重要战略部署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179421577","title":"Savara再次向美国食品和药物管理局提交Molbreevi的生物许可申请以治疗自身免疫性肺泡蛋白沉积症","url":"https://stock-news.laohu8.com/highlight/detail?id=1179421577","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179421577?lang=zh_cn&edition=full","pubTime":"2025-12-22 21:31","pubTimestamp":1766410282,"startTime":"0","endTime":"0","summary":"Savara再次向美国食品和药物管理局提交生物许可申请(BLA)，以期为自身免疫性肺泡蛋白沉积症(Autoimmune PAP)提供Molbreevi的潜在治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104472090","title":"Savara宣布欧洲专利局计划授予Molbreevi液体制剂专利","url":"https://stock-news.laohu8.com/highlight/detail?id=1104472090","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104472090?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:06","pubTimestamp":1765458399,"startTime":"0","endTime":"0","summary":"Savara宣布欧洲专利局计划授予Molbreevi液体制剂专利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192654143","title":"Master Tec任命钟鹏康为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1192654143","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192654143?lang=zh_cn&edition=full","pubTime":"2025-11-21 19:14","pubTimestamp":1763723672,"startTime":"0","endTime":"0","summary":"11月21日 - Master Tec Group Bhd宣布任命钟鹏康为首席财务官。有关公司的更多信息请见MAST.KL。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102629162","title":"万事达科技集团季度净利润达860万令吉","url":"https://stock-news.laohu8.com/highlight/detail?id=1102629162","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102629162?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:46","pubTimestamp":1763721993,"startTime":"0","endTime":"0","summary":"11月21日 - 万事达科技集团Bhd报告称：季度净利润为860万令吉，季度收入为1.158亿令吉。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152895044","title":"Savara第三季度净收入为负2956.1万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152895044","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152895044?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:33","pubTimestamp":1763573620,"startTime":"0","endTime":"0","summary":"11月12日 - Savara第三季度营业收入为负3025.5万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133223112","title":"Mastek任命Deepak Kedia为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1133223112","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133223112?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:31","pubTimestamp":1762871515,"startTime":"0","endTime":"0","summary":"11月11日 - Mastek Ltd宣布任命Deepak Kedia为首席财务官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126678734","title":"Savara与Rtw达成7500万美元的特许权资助协议以支持Molbreevi*在自身免疫性肺泡蛋白沉积症中的潜在上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1126678734","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126678734?lang=zh_cn&edition=full","pubTime":"2025-10-30 04:02","pubTimestamp":1761768133,"startTime":"0","endTime":"0","summary":"Savara与Rtw达成7500万美元的特许权资助协议，以支持Molbreevi*在自身免疫性肺泡蛋白沉积症（Autoimmune Pap）中的潜在上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517794858","title":"Savara, Inc.盘中异动 急速上涨5.44%报2.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517794858","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517794858?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:31","pubTimestamp":1741185084,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时31分，Savara, Inc.股票出现异动，股价大幅拉升5.44%。截至发稿，该股报2.52美元/股，成交量3.8759万股，换手率0.02%，振幅4.60%。Savara, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为323.50%、252.09%、185.06%，振幅较大的相关个股有Aditxt, Inc.、Tango Therapeutics, Inc.、天境生物，振幅分别为23.90%、11.41%、11.10%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223124abe9b083&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223124abe9b083&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510090333","title":"Savara, Inc.盘中异动 早盘股价大跌5.02%报2.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510090333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510090333?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:13","pubTimestamp":1739286836,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时13分，Savara, Inc.股票出现波动，股价急速下挫5.02%。截至发稿，该股报2.65美元/股，成交量5.2158万股，换手率0.03%，振幅4.30%。Savara, Inc.股票所在的生物技术行业中，整体跌幅为1.53%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2542.50%、824.87%、338.67%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为52.11%、43.92%、37.99%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112313569881c543&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112313569881c543&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVRA","OCEA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com","stockEarnings":[{"period":"1week","weight":-0.0492},{"period":"1month","weight":-0.0233},{"period":"3month","weight":-0.1052},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.5737},{"period":"ytd","weight":-0.1675}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Savara Inc.于1995年12月在特拉华州注册成立。该公司是一家专注于罕见呼吸道疾病的临床阶段生物制药公司。其唯一的项目molgramostim吸入溶液（MOLBREEVI）是一种研究性吸入式生物制剂，正处于治疗自身免疫性肺泡蛋白沉积症的3期开发阶段，并已获得快速通道、突破性疗法和孤儿药资格认定。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.103891},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.038506},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.017596},{"month":4,"riseRate":0.571429,"avgChangeRate":0.026914},{"month":5,"riseRate":0.692308,"avgChangeRate":0.023552},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.033774},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.023739},{"month":8,"riseRate":0.538462,"avgChangeRate":0.016257},{"month":9,"riseRate":0.538462,"avgChangeRate":0.011115},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.136764},{"month":11,"riseRate":0.538462,"avgChangeRate":0.131385},{"month":12,"riseRate":0.538462,"avgChangeRate":0.21983}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Savara Inc(SVRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Savara Inc(SVRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}